A Limited Access Phase II Trial of Weekly Topotecan (NSC 609699), Paclitaxel (NSC 673089), and Cisplatin (NSC 119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix.

Trial Profile

A Limited Access Phase II Trial of Weekly Topotecan (NSC 609699), Paclitaxel (NSC 673089), and Cisplatin (NSC 119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Topotecan (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2009 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 12 Feb 2009 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
    • 18 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top